Early phase II clinical study with AT-877ER in patients with pulmonary arterial hypertensio

Phase 2

• Conditions: Pulmonary arterial hypertension

• Registration Number: JPRN-jRCT2080220801
• Lead Sponsor: ASAHI KASEI PHARMA CORPORATIO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-08-12
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Aged 20 years and over at the time of consent
(2) Able to be hospitalized at the start and the end of study treatment; however, subjects may be treated on both an inpatient and outpatient basis at the time of consent
(3) Class I to III according to the World Health Organization (WHO) Pulmonary Hypertension Functional Classification at the time of consent

Exclusion Criteria

(1) Use of catecholamines and/or PDE3 inhibitors for the treatment of cardiac failure at the time of consent
(2) Serious cardiac disorder not caused by pulmonary arterial hypertension, such as angina pectoris, myocardial infarction and myocarditis
(3) Previous participation in this study

Study & Design

• Study Type: Interventional
• Study Design: Not specified